Abstract 781P
Background
Precision medicine for cancer patients has brought effective novel therapy options over the past decades. However, treatment for high-risk ovarian cancer is still based on platinum containing chemotherapy. Around 30% of primary disease patients do not respond, and 40% of complete responders relapse within a year. Strong predictive markers are lacking. This study reports a predictive chemotherapy sensitivity score to support patient-centred and better informed treatment decisions.
Methods
89 ovarian cancer patients eligible for chemotherapy were included in the trial between 2019 and 2022 in the Netherlands (IRB P18.032). Tumour clusters were isolated from ascites and solid tumour, seeded into a 384-well plate, and exposed to carboplatin, paclitaxel, three second-line chemotherapies, PARPi, and six immunotherapies. Next, ex vivo drug sensitivity was quantified using high-throughput 3D imaging and extraction of morphological features. The chemotherapy sensitivity score was generated by correlation of the assay results with the patients' response to carboplatin-paclitaxel. In parallel, patients’ relative sensitivity to other chemo-, targeted- and immunotherapies was assessed.
Results
The platform enabled accurate prediction of carboplatin-paclitaxel with a classification accuracy of 80%. Differential ex vivo patient response profiles were observed across second-line therapies, and 11% of the samples demonstrated a strong response to at least one of the immune compounds, indicating that our test method could provide alternative treatment options. For doxorubicin, the ex vivo results match clinical response (n=3), providing further evidence for the predictivity of the assay. Importantly, the assay has a success rate of 89%.
Conclusions
The prediction of clinical response to first-line therapy and identification of patient-specific sensitivity to ten second-line therapies in parallel, allows the support of informed treatment decisions for multiple treatment classes. Its two-week timeline makes the assay applicable in a clinical environment. A prospective trial for patients with suboptimal response and recurrent disease is ongoing.
Clinical trial identification
CME LUMC-P18.032.
Editorial acknowledgement
Legal entity responsible for the study
Leiden University Medical Center Radboud University Medical Center.
Funding
VitroScan B.V.
Disclosure
C.D. de Kroon: Other, Personal, Local PI: LUMC. A. van Altena: Other, Personal, Local PI: Radboud UMC. D. van der Meer, L. Ceton, J. van der Valk, T. Sijsenaar: Financial Interests, Personal, Full or part-time Employment: VitroScan. F. Grillet, M. Garcia Montero: Non-Financial Interests, Personal, Non-financial benefits: VitroScan. W. Vader: Financial Interests, Personal, Stocks or ownership: VitroScan; Financial Interests, Personal, Full or part-time Employment: VitroScan. P.B. Ottevanger: Non-Financial Interests, Personal, Local PI: Radboud UMC. J.R. Kroep: Non-Financial Interests, Personal, Local PI: LUMC.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11